TERB2

Across TCGA pan-cancer cohorts, TERB2 RNA differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of TERB2’s most consistent transcriptional readouts.

The strongest signal is observed in thyroid carcinoma (THCA), where TERB2 RNA is repressed in tumor relative to normal tissue. In most cancer types TERB2 is over-expressed in tumor, although a few such as THCA and CHOL show the opposite, repressed pattern.

THCA, CHOL, and LUSC are the cancer types where TERB2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TERB2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
THCA	Female	II,III,IV	−0.153	<.001	6	view →
CHOL	Male	All	−0.786	<.001	5	view →
LUSC	Male	II,III,IV	−0.063	<.001	5	view →
KIRC	Female	All	−0.014	.003	5	view →
LIHC	Female	II,III,IV	−0.799	<.001	4	view →
PRAD	All	All	−0.180	.043	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

TERB2–THCA

Open the THCA breakdown →